{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:16Z","timestamp":1789140676853,"version":"build-2803163510"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the therapeutic efficacy and safety of FOLFOXIRI triplet chemotherapy with FOLFIRI combined with hepatic arterial infusion chemotherapy (HAIC) in patients with unresectable colorectal liver metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center retrospective cohort study conducted at the Department of Medical Oncology, The Affiliated Hospital of Yichun University. A total of 132 patients with unresectable colorectal liver metastases treated between January 2019 and December 2023 were included. Patients were divided into the FOLFOXIRI group (n = 67) and the FOLFIRI plus HAIC group (n = 65). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), conversion-to-resection outcomes, and adverse events. Survival outcomes were evaluated using Kaplan\u2013Meier analysis and Cox proportional hazards regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The FOLFIRI plus HAIC group showed a higher ORR than the FOLFOXIRI group [37\/65 (56.9%) vs. 30\/67 (44.8%), p = 0.163] and a higher DCR [58\/65 (89.2%) vs. 46\/67 (68.7%), p = 0.004]. Kaplan\u2013Meier analysis demonstrated significantly longer PFS in the FOLFIRI plus HAIC group than in the FOLFOXIRI group (10.3 vs. 8.2 months; log-rank p = 0.038). In the unadjusted Cox model, FOLFIRI plus HAIC was associated with improved PFS (HR\u00a0=\u00a00.62, 95% CI, 0.43\u20130.89; p = 0.009). Median OS was numerically longer in the FOLFIRI plus HAIC group than in the FOLFOXIRI group (19.5 vs. 17.9 months), but the difference was not statistically significant (log-rank p = 0.150; Cox HR\u00a0=\u00a00.93, 95% CI, 0.61\u20131.42; p = 0.739). The R0 resection rate was higher in the FOLFIRI plus HAIC group [14\/65 (21.5%) vs. 6\/67 (9.0%); p = 0.044]. Grade 3\/4 adverse events were comparable between groups [20\/65 (30.8%) vs. 26\/67 (38.8%); p = 0.333], while grade 3\/4 neutropenia showed a borderline lower incidence in the FOLFIRI plus HAIC group [12\/65 (18.5%) vs. 19\/67 (28.4%); p = 0.051]. HAIC-related complications were infrequent and manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>FOLFIRI plus HAIC was associated with improved disease control, prolonged PFS, and a higher R0 resection rate compared with FOLFOXIRI. The regimen showed a manageable safety profile, with infrequent HAIC-related complications. Given the retrospective and non-randomized design, these findings should be interpreted cautiously and validated in prospective randomized studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1794578","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:41:14Z","timestamp":1781757674000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative study of triple intravenous chemotherapy versus dual chemotherapy combined with hepatic arterial infusion in patients with liver metastases from colorectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Aimin","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Yichun People's Hospital","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yichun People's Hospital","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chijin","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yichun People's Hospital","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Yichun People's Hospital","place":["Yichun, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01037-7","article-title":"Novel colorectal cancer screening methods - opportunities and challenges","volume":"22","author":"McCabe","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.04.003","article-title":"AGA clinical practice update on current role of blood tests for colorectal cancer screening: commentary","volume":"23","author":"Shaukat","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102696","article-title":"Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma","volume":"124","author":"Bernardi","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334618","article-title":"Pericyte drives the formation of circulating tumour cell-neutrophil clusters to promote colorectal cancer metastasis","volume":"75","author":"Wang","year":"2025","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-2498","article-title":"A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer","volume":"31","author":"West","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd012757.pub2","article-title":"Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases","volume":"8","author":"Swierz","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-0879","article-title":"Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trial","volume":"31","author":"Ballhausen","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/life15071071","article-title":"Gastrointestinal cancers with consideration of DPD and UGT1A1 plasma levels: chemotherapy-related toxicity","volume":"15","author":"Minchev","year":"2025","journal-title":"Life (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer","volume":"11","author":"Audisio","year":"2025","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2025.100910","article-title":"Adjuvant HAIC combined with anlotinib and TQB2450 for resected high-risk hepatocellular carcinoma","volume":"6","author":"Zhang","year":"2025","journal-title":"Innovation (Camb)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8857","DOI":"10.1038\/s41467-024-52700-z","article-title":"Apatinib plus hepatic arterial infusion of oxaliplatin and raltitrexed for hepatocellular carcinoma with extrahepatic metastasis: phase II trial","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-024-10887-1","article-title":"Safety and efficacy of percutaneous arterial port Implantation for Hepatic Arterial Infusion Chemotherapy","volume":"35","author":"Meyblum","year":"2025","journal-title":"Eur Radiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115154","article-title":"Safety and efficacy of adjuvant FOLFOX\/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial","volume":"214","author":"Wang","year":"2025","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jamaoncol.2024.5174","article-title":"First-line systemic treatment for initially unresectable colorectal liver metastases: post hoc analysis of the CAIRO5 randomized clinical trial","volume":"11","author":"Bond","year":"2025","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1640970","article-title":"Hepatic arterial infusion chemotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a meta-analysis of survival outcomes","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-009-9547-1","article-title":"Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer","volume":"32","author":"Seki","year":"2009","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1794578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:41:18Z","timestamp":1781757678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1794578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1794578"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1794578","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"article-number":"1794578"}}